Results for tag: "Pancreatic Neuroendocrine Tumor Drug"

Pancreatic Neuroendocrine Tumors (PNETs) are a rare type of pancreatic cancer that originate in the hormone-producing cells of the pancreas. Treatment for PNETs is typically a combination of surgery, chemotherapy, and targeted therapies. Drug therapies for PNETs are designed to target the specific genetic mutations that cause the tumor to grow. These drugs are typically used in combination with other treatments to improve outcomes. The Pancreatic Neuroendocrine Tumor Drug market is a rapidly growing segment of the Pancreatic Cancer Drugs market. Companies in this market are focused on developing drugs that target the specific genetic mutations that cause PNETs. These drugs are designed to be used in combination with other treatments to improve outcomes. Some companies in the Pancreatic Neuroendocrine Tumor Drug market include Novartis, Pfizer, Merck, and Eli Lilly. Show Less Read more